Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthieu Foll

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Journal of Neuroendocrinology|May 16, 2024
Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task forceAnna Koumarianou, Pier Luigi Filosso, Lisa Bodei, et al.
Cancers|December 2, 2020
Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary <i>TERT</i> Promoter Mutations as Non-Invasive Biomarkers for Detection of Urothelial CancerMd Ismail Hosen, Nathalie Forey, Geoffroy Durand, et al.
Ebiomedicine|February 22, 2020
Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort StudyMd Ismail Hosen, Mahdi Sheikh, Maria Zvereva, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 24, 2024
Identification of Defined Molecular Subgroups on the Basis of Immunohistochemical Analyses and Potential Therapeutic Vulnerabilities of Pulmonary CarcinoidsDaphne J G Leunissen, Laura Moonen, Jan H von der Thüsen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 26, 2015
A Novel Risk Locus at 6p21.3 for Epstein-Barr Virus-Positive Hodgkin LymphomaManon Delahaye-Sourdeix, Kevin Y Urayama, Valérie Gaborieau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2024
<i>TERT</i> Expression and Clinical Outcome in Pulmonary CarcinoidsLisa Werr, Christoph Bartenhagen, Carolina Rosswog, et al.
Journal of the National Cancer Institute|May 5, 2022
Genetic Analysis of Lung Cancer and the Germline Impact on Somatic Mutation BurdenAurélie A G Gabriel, Joshua R Atkins, Ricardo C C Penha, et al.
Cancer Cell|December 12, 2023
Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sitesTalya L Dayton, Nicolas Alcala, Laura Moonen, et al.
Ebiomedicine|October 26, 2019
Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactionsNicolas Alcala, Lise Mangiante, Nolwenn Le-Stang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 24, 2019
EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary ApproachAndrew G Nicholson, Jennifer L Sauter, Anna K Nowak, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Journal of Neuroendocrinology|May 16, 2024
Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task forceAnna Koumarianou, Pier Luigi Filosso, Lisa Bodei, et al.
Cancers|December 2, 2020
Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary <i>TERT</i> Promoter Mutations as Non-Invasive Biomarkers for Detection of Urothelial CancerMd Ismail Hosen, Nathalie Forey, Geoffroy Durand, et al.
Ebiomedicine|February 22, 2020
Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort StudyMd Ismail Hosen, Mahdi Sheikh, Maria Zvereva, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 24, 2024
Identification of Defined Molecular Subgroups on the Basis of Immunohistochemical Analyses and Potential Therapeutic Vulnerabilities of Pulmonary CarcinoidsDaphne J G Leunissen, Laura Moonen, Jan H von der Thüsen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 26, 2015
A Novel Risk Locus at 6p21.3 for Epstein-Barr Virus-Positive Hodgkin LymphomaManon Delahaye-Sourdeix, Kevin Y Urayama, Valérie Gaborieau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2024
<i>TERT</i> Expression and Clinical Outcome in Pulmonary CarcinoidsLisa Werr, Christoph Bartenhagen, Carolina Rosswog, et al.
Journal of the National Cancer Institute|May 5, 2022
Genetic Analysis of Lung Cancer and the Germline Impact on Somatic Mutation BurdenAurélie A G Gabriel, Joshua R Atkins, Ricardo C C Penha, et al.
Cancer Cell|December 12, 2023
Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sitesTalya L Dayton, Nicolas Alcala, Laura Moonen, et al.
Ebiomedicine|October 26, 2019
Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactionsNicolas Alcala, Lise Mangiante, Nolwenn Le-Stang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 24, 2019
EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary ApproachAndrew G Nicholson, Jennifer L Sauter, Anna K Nowak, et al.
Pageof 8